Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00099372
Other study ID # PFD 001; U01HD41249
Secondary ID U01HD041249U10HD
Status Terminated
Phase
First received
Last updated
Start date May 2004
Est. completion date June 2011

Study information

Verified date December 2020
Source NICHD Pelvic Floor Disorders Network
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Colpopexy and Urinary Reduction Effort (CARE) trial is a research study designed to evaluate whether the addition of a second surgical procedure in addition to a procedure for female pelvic organ prolapse (POP) affects the rates of urinary incontinence. This study will follow women in the CARE study for 10 years from the time of the surgery to compare success and complication rates in the two groups. Recruitment into this study is open only to women that already participated in CARE. Recruitment into CARE is closed.


Description:

The primary aims of this prospective cohort study are: 1. To determine the long-term (up to 10 years) anatomic success rate of sacrocolpopexy (defined as Stage 0 apical prolapse AND <= Stage 2 anterior and posterior prolapse AND no re-operation or pessary treatment for POP), and whether anatomic success differs between women who had vs. those who did not have concomitant Burch colposuspension at the time of sacrocolpopexy; 2. To determine whether there is a difference in long-term stress continence (by symptoms) between women who had vs. those who did not have concomitant Burch colposuspension at the time of sacrocolpopexy; 3. To determine whether there is a long-term difference between overall pelvic floor symptoms and pelvic-floor specific quality of life between women who had vs. those who did not have concomitant Burch colposuspension at the time of sacrocolpopexy.


Recruitment information / eligibility

Status Terminated
Enrollment 215
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Female
Age group 21 Years and older
Eligibility Inclusion Criteria: - Women enrolled in CARE Exclusion Criteria: - Inability to provide informed consent. - Subjects who, at the time of enrollment into E-CARE, are long-term residents of a skilled nursing facility (that is, residency is not limited to short-term rehabilitation).

Study Design


Locations

Country Name City State
United States Johns Hopkins School of Medicine Baltimore Maryland
United States The University of Alabama at Birmingham Birmingham Alabama
United States Duke University Durham North Carolina
United States University of Iowa Iowa City Iowa
United States USCD Medical Center La Jolla California
United States Loyola University Medical Center Maywood Illinois
United States Magee-Womens Hospital Pittsburgh Pennsylvania
United States Kaiser Permanente San Diego California

Sponsors (8)

Lead Sponsor Collaborator
NICHD Pelvic Floor Disorders Network Baylor College of Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Johns Hopkins University, Loyola University, University of Iowa, University of North Carolina, Chapel Hill, University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Symptomatic Failure Symptom of bulge on Pelvic Floor Distress Inventory, interval prolapse surgery, or pessary used after index surgery 24 months
Primary Number of Participants With Symptomatic Failure Symptom of bulge on Pelvic Floor Distress Inventory, interval prolapse surgery, or pessary used after index surgery 3 year
Primary Number of Participants With Symptomatic Failure Symptom of bulge on Pelvic Floor Distress Inventory, interval prolapse surgery, or pessary used after index surgery 4 year
Primary Number of Participants With Symptomatic Failure Symptom of bulge on Pelvic Floor Distress Inventory, interval prolapse surgery, or pessary used after index surgery 5 year
Primary Number of Participants With Symptomatic Failure Symptom of bulge on Pelvic Floor Distress Inventory, interval prolapse surgery, or pessary used after index surgery 6 year
Primary Number of Participants With Symptomatic Failure Symptom of bulge on Pelvic Floor Distress Inventory, interval prolapse surgery, or pessary used after index surgery 7 year
Primary Number of Participants With Anatomic Failure (Original Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex decends >= 2 cm, or the anterior or posterior vaginal wall decends >1 cm beyond the hymen 24 months
Primary Number of Participants With Anatomic Failure (Original Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex decends >= 2 cm, or the anterior or posterior vaginal wall decends >1 cm beyond the hymen 3 year
Primary Number of Participants With Anatomic Failure (Original Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex decends >= 2 cm, or the anterior or posterior vaginal wall decends >1 cm beyond the hymen 4 year
Primary Number of Participants With Anatomic Failure (Original Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex decends >= 2 cm, or the anterior or posterior vaginal wall decends >1 cm beyond the hymen 5 year
Primary Number of Participants With Anatomic Failure (Original Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex decends >= 2 cm, or the anterior or posterior vaginal wall decends >1 cm beyond the hymen 6 year
Primary Number of Participants With Anatomic Failure (Original Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex decends >= 2 cm, or the anterior or posterior vaginal wall decends >1 cm beyond the hymen 7 year
Primary Number of Participants With Anatomic Failure (Updated Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex descends below the upper third of the vagina, or the anterior (Ba) or posterior (Bp) vaginal wall prolapses beyond the hymen 24 months
Primary Number of Participants With Anatomic Failure (Updated Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex descends below the upper third of the vagina, or the anterior (Ba) or posterior (Bp) vaginal wall prolapses beyond the hymen 3 year
Primary Number of Participants With Anatomic Failure (Updated Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex descends below the upper third of the vagina, or the anterior (Ba) or posterior (Bp) vaginal wall prolapses beyond the hymen 4 year
Primary Number of Participants With Anatomic Failure (Updated Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex descends below the upper third of the vagina, or the anterior (Ba) or posterior (Bp) vaginal wall prolapses beyond the hymen 5 year
Primary Number of Participants With Anatomic Failure (Updated Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex descends below the upper third of the vagina, or the anterior (Ba) or posterior (Bp) vaginal wall prolapses beyond the hymen 6 year
Primary Number of Participants With Anatomic Failure (Updated Definition) Reoperation or pessary for POP or POP-Q measurements as follows: Vaginal apex descends below the upper third of the vagina, or the anterior (Ba) or posterior (Bp) vaginal wall prolapses beyond the hymen 7 year
Primary Number of Participants With Composite Failure Anatomic failure (updated definition) or symptomatic failure 24 months
Primary Number of Participants With Composite Failure Anatomic failure (updated definition) or symptomatic failure 3 year
Primary Number of Participants With Composite Failure Anatomic failure (updated definition) or symptomatic failure 4 year
Primary Number of Participants With Composite Failure Anatomic failure (updated definition) or symptomatic failure 5 year
Primary Number of Participants With Composite Failure Anatomic failure (updated definition) or symptomatic failure 6 year
Primary Number of Participants With Composite Failure Anatomic failure (updated definition) or symptomatic failure 7 year
Primary Number of Participants Considered as Failures For Urinary Incontinence Using the Incontinence Severity Index Failure is indicated by a score of 3 or greater on the Incontinence Severity Index (formerly called Hunskaar). The score is calculated as the product of the answers to two incontinence-related questions resulting in a range from 0 to 12 (higher scores indicating more severe symptoms). A score of 3 or greater corresponds to a severity classification of moderate, severe, or very severe. 24 months
Primary Number of Participants Considered as Failures For Urinary Incontinence Using the Incontinence Severity Index Failure is indicated by a score of 3 or greater on the Incontinence Severity Index (formerly called Hunskaar). The score is calculated as the product of the answers to two incontinence-related questions resulting in a range from 0 to 12 (higher scores indicating more severe symptoms). A score of 3 or greater corresponds to a severity classification of moderate, severe, or very severe. 3 year
Primary Number of Participants Considered as Failures For Urinary Incontinence Using the Incontinence Severity Index Failure is indicated by a score of 3 or greater on the Incontinence Severity Index (formerly called Hunskaar). The score is calculated as the product of the answers to two incontinence-related questions resulting in a range from 0 to 12 (higher scores indicating more severe symptoms). A score of 3 or greater corresponds to a severity classification of moderate, severe, or very severe. 4 year
Primary Number of Participants Considered as Failures For Urinary Incontinence Using the Incontinence Severity Index Failure is indicated by a score of 3 or greater on the Incontinence Severity Index (formerly called Hunskaar). The score is calculated as the product of the answers to two incontinence-related questions resulting in a range from 0 to 12 (higher scores indicating more severe symptoms). A score of 3 or greater corresponds to a severity classification of moderate, severe, or very severe. 5 year
Primary Number of Participants Considered as Failures For Urinary Incontinence Using the Incontinence Severity Index Failure is indicated by a score of 3 or greater on the Incontinence Severity Index (formerly called Hunskaar). The score is calculated as the product of the answers to two incontinence-related questions resulting in a range from 0 to 12 (higher scores indicating more severe symptoms). A score of 3 or greater corresponds to a severity classification of moderate, severe, or very severe. 6 year
Primary Number of Participants Considered as Failures For Urinary Incontinence Using the Incontinence Severity Index Failure is indicated by a score of 3 or greater on the Incontinence Severity Index (formerly called Hunskaar). The score is calculated as the product of the answers to two incontinence-related questions resulting in a range from 0 to 12 (higher scores indicating more severe symptoms). A score of 3 or greater corresponds to a severity classification of moderate, severe, or very severe. 7 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) Prevention One or more SUI symptoms reported on the Pelvic Floor Distress Inventory, receipt of interval anti-incontinence surgery, or receipt of an urethral bulking agent injection for SUI 24 months
Primary Number of Participants With Stress Urinary Incontinence (SUI) Prevention One or more SUI symptoms reported on the Pelvic Floor Distress Inventory, receipt of interval anti-incontinence surgery, or receipt of an urethral bulking agent injection for SUI 3 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) Prevention One or more SUI symptoms reported on the Pelvic Floor Distress Inventory, receipt of interval anti-incontinence surgery, or receipt of an urethral bulking agent injection for SUI 4 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) Prevention One or more SUI symptoms reported on the Pelvic Floor Distress Inventory, receipt of interval anti-incontinence surgery, or receipt of an urethral bulking agent injection for SUI 5 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) Prevention One or more SUI symptoms reported on the Pelvic Floor Distress Inventory, receipt of interval anti-incontinence surgery, or receipt of an urethral bulking agent injection for SUI 6 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) Prevention One or more SUI symptoms reported on the Pelvic Floor Distress Inventory, receipt of interval anti-incontinence surgery, or receipt of an urethral bulking agent injection for SUI 7 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) One or more SUI symptoms reported on the Pelvic Floor Distress Inventory 24 months
Primary Number of Participants With Stress Urinary Incontinence (SUI) One or more SUI symptoms reported on the Pelvic Floor Distress Inventory 3 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) One or more SUI symptoms reported on the Pelvic Floor Distress Inventory 4 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) One or more SUI symptoms reported on the Pelvic Floor Distress Inventory 5 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) One or more SUI symptoms reported on the Pelvic Floor Distress Inventory 6 year
Primary Number of Participants With Stress Urinary Incontinence (SUI) One or more SUI symptoms reported on the Pelvic Floor Distress Inventory 7 year
See also
  Status Clinical Trial Phase
Recruiting NCT05534412 - A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence N/A
Recruiting NCT05515198 - Improving Care for Women With Urinary Incontinence (EMPOWER) N/A
Completed NCT04071301 - Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence N/A
Completed NCT03623880 - Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders N/A
Recruiting NCT05880862 - Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Early Phase 1
Recruiting NCT04159467 - Effect of Pelvic Floor Muscle Training on Urinary Incontinence Reports in Obese Women Undergoing a Low Calorie Diet N/A
Completed NCT05485922 - Performance of a Single-use Intermittent Micro-hole Zone Catheter N/A
Completed NCT06268782 - The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women N/A
Not yet recruiting NCT03027986 - Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy N/A
Recruiting NCT02490917 - ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence N/A
Enrolling by invitation NCT02529371 - Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients N/A
Enrolling by invitation NCT02530372 - Feasibility of the UriCap-F for Urine Collection in Hospitalized Women N/A
Completed NCT02338726 - Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study N/A
Completed NCT02549729 - Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy N/A
Completed NCT02600676 - Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis N/A
Completed NCT02368262 - Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy N/A
Completed NCT02239796 - Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence N/A
Completed NCT01942681 - Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride N/A
Recruiting NCT01804153 - Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO) Phase 1/Phase 2
Completed NCT01520948 - Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease Phase 3

External Links